Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
复制标题
DOI：
10.1038/sj.leu.2404586
复制
发表时间：
2007-04-01
期刊：
影响因子：
11.4
通讯作者：
van Dongen, J. J. M.
中科院分区：
文献类型：
--
作者：
van der Velden, V. H. J.;Cazzaniga, G.;van Dongen, J. J. M.
大多数急性淋巴细胞白血病（ALL）的现代治疗方案包括微小残留病（MRD）的分析。为了确保不同MRD聚合酶链反应（PCR）实验室之间的MRD结果具有可比性，标准化和质量控制至关重要。欧洲ALL MRD检测研究组（ESG-MRD-ALL）由全球30个MRD-PCR实验室组成，已制定了基于实时定量PCR的MRD数据解读指南。这些指南的应用确保了相同基于MRD的临床方案的不同实验室之间MRD数据的相同解释。此外，ESG-MRD-ALL指南将有助于比较不同治疗方案（包括新药）中获得的MRD数据。
Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the analysis of minimal residual disease (MRD). To ensure comparable MRD results between different MRD-polymerase chain reaction (PCR) laboratories, standardization and quality control are essential. The European Study Group on MRD detection in ALL (ESG-MRD-ALL), consisting of 30 MRD-PCR laboratories worldwide, has developed guidelines for the interpretation of real-time quantitative PCR-based MRD data. The application of these guidelines ensures identical interpretation of MRD data between different laboratories of the same MRD-based clinical protocol. Furthermore, the ESG-MRD-ALL guidelines will facilitate the comparison of MRD data obtained in different treatment protocols, including those with new drugs.